WO2002066512A1 - Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation - Google Patents

Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2002066512A1
WO2002066512A1 PCT/US2002/005211 US0205211W WO02066512A1 WO 2002066512 A1 WO2002066512 A1 WO 2002066512A1 US 0205211 W US0205211 W US 0205211W WO 02066512 A1 WO02066512 A1 WO 02066512A1
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
tripeptide
group
amino acid
inhibitory
Prior art date
Application number
PCT/US2002/005211
Other languages
English (en)
Inventor
Mark A. Scialdone
Shaker A. Mousa
Steven W. Shuey
Original Assignee
E.I. Dupont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E.I. Dupont De Nemours And Company filed Critical E.I. Dupont De Nemours And Company
Priority to JP2002566225A priority Critical patent/JP2005507363A/ja
Priority to EP02714953A priority patent/EP1360205A1/fr
Priority to CA002432932A priority patent/CA2432932A1/fr
Publication of WO2002066512A1 publication Critical patent/WO2002066512A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to methods of use and compositions for inhibiting endothelial cell tube formation, the initial step of tumor angiogenesis, and angiogenesis-dependent deseases in tissue, animals and humans. More particularly, the present invention relates to a tripeptide, its analogues, mimetics and chemical derivatives that show inhibition of angiogenesis-mediated processes such as cancer, ocular neovascularization, and inflammatory diseases. Anti-angiogenesis agents disclosed can be also used in conjunction with surgery, chemotherapy, radiotherapy, and laser therapy.
  • Angiogenesis is the development of new blood vessels from preexisting blood vessels (Mousa, S. A., In Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, Austin Bioscience, Georgetown, TX; Chapter 1 , (2000)).
  • angiogenesis ensures proper development of mature organisms, prepares the womb for egg implantation and plays a key role in wound healing.
  • angiogenesis supports the pathological conditions associated with a number of disease states such as cancer, inflammation and ocular diseases.
  • VEGF Vascular endothelial growth factor
  • bFGF vascular endothelial growth factor
  • IL-8 vascular endothelial growth factor
  • TNF-a vascular endothelial growth factor
  • Angiogenesis is generally absent in adult or mature tissues, although it does occur in wound healing and in embryogenesis (Moses et al., Science 248:1408-1410 (1990)).
  • Angiogenesis or "neovascularization" is a multi-step process controlled by the balance of pro- and anti-angiogenic factors.
  • endothelial cells EC
  • FGF2 and VEGF growth factors
  • FGF2 and VEGF growth factors
  • the endothelial cell is the pivotal component of the angiogenic process and responds to many cytokines through its cell surface receptors and intracellular signaling mechanisms.
  • Endothelial cells in culture are capable of forming tube-like structures that possess lumens. Therefore, endothelial cells are not only a prerequisite for neovascularization, but appear to be the basal structural requirement as well.
  • Angiogenesis-dependent diseases include the following: inflammatory disorders such as immune and non-immune inflammation, rheumatoid arthritis, psoriasis; ocular disorders such as diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, age- related macular degeneration, corneal graft rejection; and cancer associated disorders such as solid tumors, tumor metastases, and blood born tumors such as leukemia, angiofibroma, kaposi sarcoma, benign tumors, as well as other cancers, which require neovascularization to support tumor growth.
  • inflammatory disorders such as immune and non-immune inflammation, rheumatoid arthritis, psoriasis
  • ocular disorders such as diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, age- related macular degeneration, corneal graft rejection
  • cancer associated disorders such as solid tumors, tumor metastases
  • angiogenesis would be a useful therapy for restricting tumor growth.
  • Inhibition of angiogenesis can be achieved by inhibiting endothelial cell response to angiogenic stimuli as suggested by Folkman et al., (Cancer Biology 3:89-96 (1992)), where it described examples of those endothelial cell response inhibitors such as angiostatic steroids, fungal derived products such fumagilin, platelet factor 4, thrombospondin, alpha-interferon, vitamin D analogs and D- penicillamine.
  • endothelial cell response inhibitors such as angiostatic steroids, fungal derived products such fumagilin, platelet factor 4, thrombospondin, alpha-interferon, vitamin D analogs and D- penicillamine.
  • the problem to be solved is to provide the identification of a small recognition epitope which would be the crucial step in providing a template for structure-based drug design strategies towards small molecule analogues or peptidomimetics.
  • small molecules would include cyclic peptides and peptide isosteres with preferable physiochemical and pharmacokinetic properties that intervene in angiogenesis-dependent diseases such as cancer.
  • the invention is directed toward an angiogenesis-inhibitory tripeptide of formula aa1-aa2-aa3, having a first amino acid (aa1), a second amino acid (aa2) and a third amino acid (aa3), wherein, (a) said first amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gin, Glu, Asp, Asn, His, Met, lie, Trp, Val, diaminoproprionic acid and -ra.7s-4-hydroxy-proline; (b) said second amino acid is selected from the group consisting of Asn, Ala, Gly, Asp, Glu, Gin diaminoproprionic acid and -rar.s-4-hydroxy-proline; and (c) said third amino acid is selected from the group consisting of Ser, Thr, Ala, Phe, Tyr, Cys, Gly, Leu, Lys, Pro, Arg, Gin,
  • Figure 1 illustrates the effect of SNS in inhibiting the human endothelial cell tube formation induced by fibroblast growth factor basic (FGF2).
  • FGF2 fibroblast growth factor basic
  • Figure 2 illustrates the effect of SNS in inhibiting FGF2-induced angiogenesis in the chorioallantoic membrane (CAM) model.
  • FIG. 3 illustrates the percent inhibition of TSU-Pr (human prostrate) tumor growth in the presence of SNS.
  • Figure 4 illustrates the anti-angiogenic effect of SNS tripeptide analogues in human endothelial tube formation and the CAM model.
  • Figure 5 illustrates the anti-angiogenic effect of SNS tripeptide analogues in the CAM model.
  • tripeptide as used herein, is intended to mean a peptide having athree amino acid residues, and includes any of the analogues, peptide mimetics, and chemical derivatives discussed herein.
  • peptide is intended to mean two or more amino acid residues covalently bonded together.
  • a peptide of the invention includes polypeptides having several hundred or more amino acid residues.
  • the covalent bond between the two or more amino acid residues is an amide bond.
  • the amino acids can be joined together by various other means known to those skilled in the peptide and chemical arts. Therefore, the term “peptide” is intended to include molecules which contain, in whole or in part, non-amide linkages between the amino acids, amino acid analogues and mimetics.
  • the term also includes cyclic peptides and other conformationally constrained structures.
  • the tripeptide of the instant invention has three amino acid residues that render angiogenesis inhibitory action in tissue, animals, and individuals.
  • One preferred tripeptide of the instant invention is characterized by the sequence serine-asparagine-serine, depicted in Structure 1 , also represented by Ser-Asn-Ser, also abbreviated in single letter amino acid code as and referred to hereinafter as "SNS".
  • the preferred amino acids are levorotatory forms and the amino-terminus is capped with an acetyl group and the carboxy-terminus is capped with carboxamide.
  • Another preferred embodiment of the instant invention is Ser-Gln- Ser, also abbreviated in single letter amino acid code as SQS, wherein the amino acids are levorotatory forms and the amino-terminus is capped with an acetyl group and the carboxy-terminus is capped with carboxamide.
  • Additional embodiments of the tripeptide of the instant invention are analogues, peptide mimetics, and chemical derivatives of Ser-Asn-Ser such that the tripeptide contains additional chemical moieties or modified amino acids not normally part of a naturally occuring protein, as will be discussed further herein.
  • capped refers to the addition of a group on the amino- or carboxy-terminus of the tripeptide.
  • the termini of the tripeptide of the present invention are preferably blocked or "capped” with an acetyl group (CH3CO-) bound to the N-terminal amino group and an amido (-NH2) group bound to the C-terminal carboxyl group of the tripeptide of the invention; which is also abbreviated as "carboxamide".
  • the tripeptide can be capped with any other group.
  • Endothelial cell is abbreviated EC.
  • FGF2 Fibroblast growth factor basic
  • CAM Chorioallantoic membrane
  • VEGF Vascular endothelial growth factor
  • frans-4-Hydroxyproline is abbreviated t4Hyp.
  • 1-Hydroxybenztriazole is abbreviated HOBt.
  • HBTU 2-(1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
  • DIEA Diaisopropylethylamine
  • DMF Dimethylforamide
  • TFA Trifluoroacetic acid
  • TIS Trimethylsilane
  • HUVEC Human umbilical vein endothelial cells
  • EGM Endothelial Cell Growth Medium
  • EBM Endothelial Cell Basal Medium
  • BS Bovine serum albumin
  • FMOC 9-Fluorenylmethyloxycarbonyl
  • the tripeptides of the present invention are preferably prepared using solid-phase synthesis, such as that generally described by Chan et al., (In FMOC Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press; Chapter 3 (2000)), although other equivalent chemical syntheses known in the art are also useful (Merrifield, J. Amer. Chem. Soc. 85:2149-54 (1963)).
  • Solid-phase peptide synthesis may be initiated from the C-terminus of the peptide by coupling a protected ⁇ -amino acid to a suitable resin.
  • Such a starting material can be prepared by attaching an ⁇ -amino acid-protected amino acid by an ester linkage to a chloromethylated resin or to a hydroxymethyl resin, or by an amide bond to a BHA resin or MBHA resin.
  • BHA and MBHA resin supports are commercially available and are generally used only when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus.
  • the amino acids can be coupled to the growing peptide chain using techniques well known in the art for the formation of peptide bonds. For example, one method involves converting the amino acid to a derivative that will render the carboxyl group of the amino acid more susceptible to reaction with the free N-terminal amino group of the growing peptide chain.
  • the C-terminal of the protected amino acid can be converted to a mixed anhydride by the reaction of the C-terminal with ethyl chloroformate, phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate, or pivaloyl chloride or other similar acid chlorides.
  • the C-terminal of the amino acid can be converted to an active ester, such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N- hydroxysuccinimide ester, or an ester formed from 1- hydroxybenzotriazole.
  • an active ester such as a 2,4,5-trichlorophenyl ester, a pentachlorophenyl ester, a pentafluorophenyl ester, a p-nitrophenyl ester, a N- hydroxysuccinimide ester, or an ester formed from 1- hydroxybenzotriazole.
  • Another coupling method involves the use of a suitable coupling agent, such as N,N'-dicyclohexylcarbodiimide or N,N'- diisopropylcarbodiimide.
  • each amino acid employed in the peptide synthesis must be protected during the coupling reaction to prevent side reactions involving their active ⁇ -amino function.
  • Certain amino acids contain reactive side-chain functional groups (e.g., sulfhydryl, amino, carboxyl, and hydroxyl) and such functional groups must also be protected with suitable protecting groups to prevent a chemical reaction from occurring at either (1) the ⁇ -amino group site or (2) a reactive side chain site during both the initial and subsequent coupling steps.
  • an ⁇ -amino protecting group (1) should render the ⁇ -amino function inert under the conditions employed in the coupling reaction, (2) should be readily removable after the coupling reaction under conditions that will not remove side-chain protecting groups and will not alter the structure of the peptide fragment, and (3) should substantially reduce the possibility of racemization upon activation, immediately prior to coupling.
  • a side-chain protecting group (1) should render the side chain functional group inert under the conditions employed in the coupling reaction, (2) should be stable under the conditions employed in removing the ⁇ -amino protecting group, and (3) should be readily removable from the desired fully-assembled peptide under reaction conditions that will not alter the structure of the peptide chain.
  • protecting groups known to be useful for peptide synthesis vary in reactivity with the agents employed for their removal.
  • certain protecting groups such as triphenylmethyl and 2-(p-biphenyl)isopropyloxycarbonyl
  • Other protecting groups such as f-butyloxycarbonyl (BOC), f-amyloxycarbonyl, adamantyl-oxycarbonyl, and p-methoxybenzyloxycarbonyl, are less labile and require moderately strong acids for their removal, such as trifluoroacetic, hydrochloric, or boron trifluoride in acetic acid.
  • Still other protecting groups such as benzyloxycarbonyl (CBZ), halobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, and isopropyloxycarbonyl, are even less labile and require even stronger acids, such as hydrogen fluoride, hydrogen bromide, or boron trifluoroacetate in trifluoroacetic acid, for their removal.
  • acids such as hydrogen fluoride, hydrogen bromide, or boron trifluoroacetate in trifluoroacetic acid
  • protecting groups are: (a) aromatic urethane-type protecting groups, such as fluorenylmethyloxycarbonyl (FMOC), CBZ, and substituted CBZ, such as, p-chlorobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p- bromobenzyloxycarbonyl, and p-methoxybenzyloxycarbonyl, o- chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 2,6- dichlorobenzyloxycarbonyl, and the like; (b) aliphatic urethane-type protecting groups, such as BOC, t- amyloxycarbonyl, isopropyloxycarbonyl, 2-(p- biphenyl)isopropyloxycarbonyl, allyloxycarbonyl and the like; and (c) cycloalkyl urethane-type protecting groups, such as fluorenylmethyloxycarbonyl (FMOC
  • the preferred ⁇ -amino protecting groups are BOC and FMOC.
  • protection may be by any of the groups mentioned above in (1) such as BOC, 2- chlorobenzyloxycarbonyl and the like.
  • protection may be provided by nitro, tosyl, CBZ, adamantyloxycarbonyl, 2,2,5,7,8-pentamethylchroman-6- sulfonyl, 2,3,6-trimethyl-4-methoxyphenylsulfonyl, or BOC groups.
  • protection may be, for example, by f-butyl; benzyl (BZL); or substituted BZL, such as p-methoxybenzyl, p-nitrobenzyl, p-chlorobenzyl, o-chlorobenzyl, and 2,6-dichlorobenzyl.
  • BZL benzyl
  • substituted BZL such as p-methoxybenzyl, p-nitrobenzyl, p-chlorobenzyl, o-chlorobenzyl, and 2,6-dichlorobenzyl.
  • protection may be, for example, by esterification using such groups as BZL, --butyl, cyclohexyl, cyclopentyl, and the like.
  • benzyloxymethyl (BOM) or tosyl moiety is suitably employed as a protecting group.
  • a protecting group such as tetrahydropyranyl, -erf-butyl, trityl, BZL, chlorobenzyl, 4-bromobenzyl, and 2,6-dichlorobenzyl are suitably employed.
  • the preferred protecting group is bromobenzyloxycarbonyl.
  • xanthyl (Xan) is preferably employed.
  • Met the amino acid is preferably left unprotected.
  • the first C-terminal amino acid of the growing peptide chain e.g., Glu
  • an appropriately selected protecting group such as BOC.
  • the BOC-Glu-( ⁇ -cyclohexyl)-OH can be first coupled to a benzylhydrylamine resin using isopropylcarbodiimide at about 25 °C for two hours with stirring or to a chloromethylated resin.
  • the ⁇ -amino protecting group is usually removed, typically by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone.
  • the ⁇ -amino group de-protection reaction can occur over a wide range of temperatures, but is usually carried out at a temperature between about 0 °C and room temperature.
  • Other standard ⁇ -amino group de-protecting reagents, such as HCI in dioxane, and conditions for the removal of specific ⁇ -amino protecting groups are within the skill of those working in the art.
  • the unprotected ⁇ -amino group can be coupled in a stepwise manner in the intended sequence.
  • Each protected amino acid or amino acid sequence is usually introduced into the solid-phase reactor in amounts in excess of stoichiometric quantities, and the coupling is suitably carried out in an organic solvent, such as dimethylformamide (DMF), methylene chloride or mixtures thereof. If incomplete coupling occurs, the coupling procedure is customarily repeated before removal of the N-amino protecting group in preparation for coupling to the next amino acid. Following the removal of the ⁇ -amino protecting group, the remaining ⁇ -amino and side-chain- protected amino acids can be coupled in a stepwise manner in the intended sequence. The success of the coupling reaction at each stage of the synthesis may be monitored. A preferred method of monitoring the synthesis is by the ninhydrin reaction.
  • the coupling reactions can also be performed automatically using well-known commercial methods and devices, for example, a Beckman 990 Peptide Synthesizer.
  • the protected peptide Upon completion of the desired peptide sequence, the protected peptide must be cleaved from the resin support, and all protecting groups must be removed.
  • the cleavage reaction and removal of the protecting groups is suitably accomplished concomitantly or consecutively with de- protection reactions.
  • the bond anchoring the peptide to the resin is an ester bond
  • it can be cleaved by any reagent that is capable of breaking an ester linkage and of penetrating the resin matrix.
  • One especially useful method is by treatment with liquid anhydrous hydrogen fluoride. This reagent will usually not only cleave the peptide from the resin, but will also remove all acid-labile protecting groups and, thus, will directly provide the fully de-protected peptide.
  • additional protecting groups that are not acid-labile are present, additional de-protection steps must be carried out. These steps can be performed either before or after the hydrogen fluoride treatment described above, according to specific needs and circumstances.
  • the hydrogen fluoride cleavage/de-protection treatment generally results in the formation of the free peptide acids.
  • a benzhydrylamine resin When a benzhydrylamine resin is used, the hydrogen fluoride treatment generally results in the free peptide amides. Reaction with hydrogen fluoride in the presence of anisole and imethylsulfide at 0 °C for one hour will typically remove the side-chain protecting groups and, release the peptide from the resin. When it is desired to cleave the peptide without removing protecting groups, the protected peptide-resin can be subjected to methanolysis, thus yielding a protected peptide in which the C-terminal carboxyl group is methylated.
  • This methyl ester can be subsequently hydrolyzed under mild alkaline conditions to give the free C-terminal carboxyl group.
  • the protecting groups on the peptide chain can then be removed by treatment with a strong acid, such as liquid hydrogen fluoride.
  • a strong acid such as liquid hydrogen fluoride.
  • methanolysis is that in which the protected peptide-resin is treated with methanol and potassium cyanide in the presence of a crown ether.
  • Other methods for cleaving a protected peptide from the resin when a chloromethylated resin is employed include (1) ammoniolysis and (2) hydrazinolysis. If desired, the resulting C-terminal amide or hydrazide can be hydrolyzed to the free C-terminal carboxyl moiety, and the protecting groups can be removed conventionally.
  • the protecting group present on the N-terminal ⁇ -amino group may be removed either before, or after, the protected peptide is cleaved from the support.
  • Purification of the peptides of the invention is typically achieved using chromatographic techniques, such as preparative HPLC (including reverse phase HPLC), gel permeation, ion exchange, partition chromatography, affinity chromatography (including monoclonal antibody columns), and the like, or other conventional techniques such as countercurrent distribution or the like.
  • chromatographic techniques such as preparative HPLC (including reverse phase HPLC), gel permeation, ion exchange, partition chromatography, affinity chromatography (including monoclonal antibody columns), and the like, or other conventional techniques such as countercurrent distribution or the like.
  • SNS tripeptides of the present invention may also be prepared using recombinant DNA technology.
  • amino acid is intended to mean both naturally occurring and non-naturally occurring amino acids, as well as amino acid analogues and mimetics.
  • Naturally occurring amino acids include the 20 (L)-amino acids utilized during protein biosynthesis as well as others, such as, 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, homocysteine, citrulline and orthinine.
  • Non-naturally occurring amino acids include, for example, (D)-amino acids, norleucine, norvaline, p-fluorophenylalanine, ethionine and the like.
  • amino acid “analogues” or peptide “analogues” include modified forms of naturally and non-naturally occurring amino acids. Such modifications can include, for example, substitution or replacement of chemical groups and moieties on the amino acid or by derivitization of the amino acid.
  • tripeptides in which at least one amino acid residue varies from the tripeptide of formula (1 ) (Ser-Asn-Ser).
  • Ser-Asn-Ser tripeptides in which at least one amino acid residue varies from the tripeptide of formula (1 )
  • Chemical Derivatives As used herein, "chemical derivatives" of the tripeptide of the present invention contain additional chemical moieties not normally a part of the tripeptide. Covalent modifications of the tripeptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
  • the amino and carboxyl termini are preferably blocked or "capped” with acetyl (CH3CO-), bound to the amino-terminal N and amido (-NH2) bound to the C-terminal carboxyl group; also abbreviated as “carboxamide”, but can be readily capped with any other group. Judicious choice of capping groups allows the addition of other activities to the peptide. For example, the presence of a sulfhydryl group linked to the N- or C-terminal cap will permit conjugation of the derivatized peptide to other molecules.
  • Some amino-terminal capping groups are compounds selected from the group consisting of acetyl, benzoyl, alkylsulfonyl, arylsulfonyl, alkylaminoacyl, arylaminoacyl, formyl, peptide and polymer.
  • Examples of carboxy-terminal groups are compounds selected from the group consisting of NH2, OH, and NHR, wherein R is selected from the group consisting of alkyl, aryl, peptide and polymer.
  • capped peptides are examples of preferred chemical derivatives of the natural (L-amino acid configuration) uncapped peptide. Any of the above combination of analogues or chemical derivatives may be capped with any of the capping groups disclosed herein.
  • an "amino acid mimetics” include, for example, organic structures which exhibit functionally similar properties such as charge and charge spacing characteristic of the reference amino acid. Mimetics also include constrained structures so as to maintain optimal spacing and charge interactions of the amino acid or of the amino acid functional groups. Those skilled in the art know or can determine what structures constitute functionally equivalent amino acid mimetics.
  • a "peptide mimetic" or peptidomimetic is an organic molecule that retains similar peptide chain pharmacophore groups as are present in the corresponding peptide. Peptide mimetics also can be functional equivalents of the particular peptide.
  • the SNS tripeptides of the invention can be grouped based on the pharmacophore properties.
  • peptide mimetic compound of the invention is one that mimics the biological effect of SNS, capped or uncapped.
  • a peptidomimetic agent may be an unnatural occurring peptide (D-amino acid configuration) or a non-peptide agent which has the stereochemical properties of the tripeptide of the present invention, capped or uncapped, such that it has the binding activity or biological activity of the tripeptide of the present invention, capped or uncapped.
  • Peptidomimetic compounds either agonists, substrates or inhibitors, have been described for a number of bioactive peptides such as opioid peptides, VIP, thrombin, HIV protease, etc.
  • bioactive peptides such as opioid peptides, VIP, thrombin, HIV protease, etc.
  • Methods for designing and preparing peptidomimetic compounds are known in the art (Kempf, D.J. Methods Enzymol. 241 :334-354 (1994); Hruby, V. J., Biopolymers 33:1073-82 (1993); Wiley et al., Med. Res. Rev. 13:327-384 (1993); Claeson, G., Blood Coagul. Fibrinolysis 5:411-436 (1994)).
  • capped or uncapped peptidomimetics which possess at least the binding capacity and specificity of the tripeptide and preferably also possess the biological activity.
  • Knowledge of peptide chemistry and general organic chemistry available to those skilled in the art are sufficient for the design and testing of such compounds.
  • such peptidomimetics may be identified by inspection of the cystallographically-derived three-dimensional structure of a peptide of the invention.
  • the structure of a tripeptide of the invention bound to its receptor(s) can be gained by the techniques of nuclear magnetic resonance spectroscopy. The better knowledge of the stereochemistry of the interaction of, for example, SNS, capped or uncapped, with its receptor will permit the rational design of such peptidomimetic agents.
  • angiogenesis inhibitory As used herein, the terms “angiogenesis inhibitory”, “angiogenesis inhibiting” or “anti-angiogenic” include vasculogenesis, and are intended to mean effecting a decrease in the extent, amount, or rate of neovascularization. Effecting a decrease in the extent, amount, or rate of endothelial cell proliferation or migration in the tissue is a specific example of inhibiting angiogenesis.
  • angiogenesis inhibitory composition refers to a composition which inhibits angiogenesis-mediated processes such as endothelial cell migration, proliferation, tube formation and subsequently leading to the inhibition of the generation of new blood vessels from existing ones, and consequently the inhibition of angiogenesis-dependent diseases.
  • angiogenesis-dependent disease is intended to mean a disease where the process of angiogenesis or vasculogenesis sustains or augments a pathological condition.
  • Angiogenesis is the formation of new blood vessels from pre-existing capillaries or post-capillary venules.
  • Vasculogenesis results from the formation of new blood vessels arising from angioblasts which are endothelial cell precursors. Both processes result in new blood vessel formation and are included in the meaning of the term angiogenesis- dependent diseases.
  • the term “angiogenesis” as used herein is intended to include de novo formation of vessels such as that arising from vasculogenesis as well as those arising from branching and sprouting of existing vessels, capillaries and venules.
  • Angiogenesis including vasculogenesis, is an important physiological process, without which embryonic development and wound healing would not occur.
  • angiogenesis is also inappropriately recruited into numerous pathological conditions as a means to provide adequate blood and nutrient supply to the cells within the affected tissue. Many of these pathological conditions involve abberant cell proliferation or regulation.
  • Such conditions in which angiogenesis is believed to be important are referred to herein as angiogenesis-dependent diseases.
  • methods of the invention also can be used beneficially to inhibit angiogenesis associated with normal physiological processes.
  • the inhibition of angiogenesis associated with the menstrual cycle can be prophylactically used as an effective method of birth control. Therefore, the description below in reference to the treatment of angiogenesis-dependent diseases are also applicable to the inhibition of normal angiogenic responses where a prophylactic or therapeutic need or benefit exists.
  • Angiogenesis-dependent desease include, for example, inflammatory disorders such as immune and non-immune inflammation, rheumatoid arthritis, chronic articular rheumatism and psoriasis; disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, retrolental fibroplasia, rubeosis, capillary proliferation in atherosclerotic plaques and osteoporosis; and cancer associated disorders, including for example, solid tumors, tumor metastases, blood born tumors such as leukemias, angiofibromas, Kaposi sarcoma, benign tumors such as hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, as well as other cancers which require neovascularization to support tumor growth.
  • inflammatory disorders such as immune and non
  • angiogenesis-dependent diseases include, for example, Osier-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints and wound granulation.
  • Other diseases in which angiogenesis plays a role in the maintenance or progression of the pathological state are known to those skilled in the art and are similarly intended to be included within the meaning of the term used herein.
  • Endothelial cells for example, human umbilical vein endothelial cells (HUVEC) or human microvascular endothelial cells (HMVEC) which can be prepared or obtained commercially, were mixed at a concentration of 2 x 105 cells/mL with fibrinogen (5 mg/mL in phosphate buffered saline (PBS) in a 1 :1 (v/v) ratio.
  • fibrinogen 5 mg/mL in phosphate buffered saline (PBS) in a 1 :1 (v/v) ratio.
  • Thrombin was added (5 units/mL final concentration) and the mixture was immediately transferred to a 24-well plate (0.5 mL per well).
  • VEGF vascular endothelial growth factor
  • FGF2 fibroblast growth factor basic
  • This assay is recognized in the art to be predictive of angiogenic efficacy (or angiogenesis inhibiting activity) in vivo (Grant et al., In Vitro Cell Dev. Biol. 27A:327-336 (1991 ); Min et al., Cancer Res. 56:2428-2433 (1996)).
  • endothelial cell tube formation is observed when endothelial cells are cultured on Matrigel® matrix-coated plates, commercially available from Becton Dickinson of Bedford, PA (Schnaper et al., J. Cell. Physiol. 165:107-118 (1995)). Endothelial cells (1 x 104 cells/well) are transferred onto Matrigel® matrix-coated 24-well plates, and tube formation is quantitated after 48 hours. Inhibitors are tested by adding them either at the same time as the endothelial cells or at various time points thereafter.
  • This assay models angiogenesis by presenting to the endothelial cells a particular type of basement membrane, namely the layer of matrix which migrating and differentiating endothelial cells might be expected to first encounter.
  • the matrix components found in Matrigel® matrix (and in basement membranes in situ) or proteolytic products thereof may also be stimulatory for endothelial cell tube formation which makes this model complementary to the fibrin gel angiogenesis model.
  • angiogenic activities of compounds of the present invention were evaluated by the chick chorioallantoic membrane (CAM) assay (Oikawa et al., Cancer Lett. 59:57-66 (1991 )).
  • CAM chick chorioallantoic membrane
  • the invention provides a method of inhibiting angiogenesis in tissue by administering an angiogenesis-inhibitory amount of the SNS tripeptide, an analogue, a mimetic or a chemical derivative thereof.
  • the invention further provides a method of treating an angiogenesis-dependent disease in an animal by administering an angiogenesis inhibitory amount of the SNS tripeptide, an analogue or a functional equivalent thereof.
  • the invention also provides a method of inhibiting agiogenesis-dependent disease in a human by administering an angiogenesis inhibitory amount of the SNS tripeptide, an analogue or a functional equivalent thereof.
  • the SNS tripeptide, its analogues, or chemical derivatives can be administered to a tumor bearing animal to determine the inhibiting activity or efficacy of the peptide on tumor growth, compared to a non-anti- angiogenesis peptide control.
  • a decrease in the rate or extent of tumor growth, or a disappearance of the tumor correlates with the anti- angiogenic activity and efficacy against progression of an angiogenesis- dependent disease.
  • the peptide can be administered within a concentration range known in the art to be indicative of an inhibitor's activity in a particular assay.
  • a concentration of a polypeptide inhibitor which yeilds indicative results in the bovine capillary endothelial cell assay is generally about
  • concentration of a polypeptide inhibitor which would yield a positive result for a polypeptide inhibitor that is active against angiogenesis in a CAM is generally about, for example, 0.5-20 ⁇ g/ml, 10-20 ⁇ g/disc, over a range of concentrations of 0.1-100 ⁇ g/disc, or 25 ⁇ g/disc.
  • An indicative concentration for a polypeptide inhibitor which would be expected to yield positive results in the rabbit corneal assay is generally about 40 ⁇ g/hydron pellet.
  • concentrations for polypeptide inhibitors which would yield indicative results in the tumor metastasis and tumor bearing animal models described above are about 250 ⁇ g twice weekly or 10 mg/kg/day for 10 days; and 12.5 ⁇ g daily or 1 mg twice a week, respectively. Further refinement can be performed by, for example, varying the concentration of the SNS tripeptide within the active concentration range to determine an optimal concentration or amount for inhibiting angiogenesis.
  • concentrations for polypeptide inhibitors which would yield indicative results in the tumor metastasis and tumor bearing animal models described above are about 250 ⁇ g twice weekly or 10 mg/kg/day for 10 days; and 12.5 ⁇ g daily or 1 mg twice a week, respectively.
  • Further refinement can be performed by, for example, varying the concentration of the SNS tripeptide within the active concentration range to determine an optimal concentration or amount for inhibiting angiogenesis.
  • the above described models, as well as other methods known to those skilled in the art can similarly be used to determine appropriate dosage regimes in regard to timing of administrations, number of administrations and
  • the above described methods also can be routinely used to make and identify new, modified or improved SNS tripeptides, analogues, mimetics or chemical derivatives.
  • SNS tripeptides analogues, mimetics or chemical derivatives.
  • those skilled in the art will know or can determine an effective amount of the SNS tripeptide, analogue, mimetic or chemical derivative to inhibit angiogenesis-dependent or to treat an angiogenesis-dependent disease.
  • angiogenesis inhibitory amount is intended to mean an amount of an SNS tripeptide, analogue, mimetic or chemical derivative of the invention required to effect a decrease in the extent, amount or rate of neovascularization when administered to a tissue, animal or individual.
  • the dosage of an SNS tripeptide, analogue, mimetic or chemical derivative required to be therapeutically effective will depend, for example, on the angiogenesis-dependent disease to be treated, the route and form of administration, the potency and big-active half-life of the molecule being administered, the weight and condition of the tissue, animal or individual, and previous or concurrent therapies.
  • the appropriate amount application of the method can be determined by those skilled in the art, using the guidance provided herein. For example, the amount can be extrapolated from in vitro or in vivo angiogenesis assays described above.
  • the condition of the patient needs to be monitored throughout the course of therapy and that the amount of the composition administered can be adjusted accordingly.
  • an angiogenesis inhibitory amount of a peptide of the invention can be, for example, between about 10 ⁇ g/kg to 500 mg/kg body weight, for example, between about 0.1 mg/kg to 100 mg/kg, or preferably between about I mg/kg to 50 mg/kg, depending on the treatment regimen. For example, if a peptide is administered from one to several times a day, then a lower dose would be needed than if a peptide were administered weekly, or monthly or less frequently. Similarly, formulations that allow for timed-release of a peptide would provide for the continuous release of a smaller amount of a peptide than would be administered as a single bolus dose. For example, a peptide can be administered at 4 mg/kg/week.
  • SNS tripeptide, analogue, mimetic or chemical derivative of the invention can be delivered systemically, such as intravenously or intraarterially.
  • An SNS tripeptide, analogue, mimetic or chemical derivative can also be administered locally at a site of angiogenesis.
  • Appropriate sites for administration of SNS tripeptide, analogue, mimetic or chemical derivative are known or can be determined by those skilled in the art depending on the clinical indications of the individual being treated.
  • the SNS tripeptides, analogues, mimetics or chemical derivatives, having inhibitory activity described above can be provided as isolated and substantially purified proteins and protein fragments as well as insoluble aggregate in pharmaceutically acceptable formulations using formulation methods known to those of ordinary skill in the art.
  • formulations can be administered by standard routes, including for example, topical, transdermal, intranasal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginai, intrauterine, oral, rectal or parenteral (e.g., intravenous, intraspinal, subcutaneous or intramuscular) routes.
  • an SNS tripeptide, analogue, mimetic or chemical derivative can be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor or implanted so that the SNS tripeptide, analogue, mimetic or chemical derivative is released systemically over time.
  • Osmotic minipump peptides, analogues, mimetics or chemical derivatives can also be used to provide controlled delivery of high concentrations of SNS tripeptide, analogue, mimetic or chemical derivative through cannulae to the site of interest, such as directly into a metastatic growth or into the vascular supply of a tumor.
  • the biodegradable polymers and their use are described, for example, in detail in Brem et al:, J. Neurosurg 74:441 -446 (19911 , which is incorporated herein by reference.
  • the SNS tripeptide, analogue, mimetic or chemical derivative can also be administered in conjunction with with an additional therapeutic compound selected from the group consisting of chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, angiogenic inhibitors, anti-edema agents, radiosensitizers and combinations thereof.
  • an additional therapeutic compound selected from the group consisting of chemotherapeutics, antibiotics, antivirals, antiinflammatories, targeting compounds, cytokines, immunotoxins, anti-tumor antibodies, angiogenic inhibitors, anti-edema agents, radiosensitizers and combinations thereof.
  • compositions of SNS tripeptide, analogue, mimetic or chemical derivative together with a pharmaceutically acceptable medium and formulations can be used in a method of the invention to inhibit angiogenesis or treat an angiogenesis-dependent disease.
  • an SNS tripeptide, analogue, mimetic or chemical derivative can be administered as a solution or suspension together with a pharmaceutically acceptable medium.
  • a pharmaceutically acceptable medium can be, for example, water, sodium phosphate buffer, phosphate buffered saline, normal saline or Ringer's solution or other physiologically buffered saline, or other solvent or vehicle such as a glycol, glycerol, an oil such as olive oil or an injectable organic ester.
  • the SNS tripeptide, analogue, mimetic or chemical derivative formulations include those applicable for parenteral administration such as subcutaneous, intraperitoneal, intramuscular, intravenous, intradermal, intracranial, intratracheal, and epidural administration. As well as formulations applicable for oral, rectal, ophthalmic (including intravitreal or intracameral), nasal, topical (including buccal and sublingual), intrauterine, or vaginal administration.
  • the SNS tripeptide, analogue, mimetic or chemical derivative formulations can be presented in unit dosage form and can be prepared by pharmaceutical techniques well known to those skilled in the art. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s).
  • the SNS tripeptide, analogue, mimetic or chemical derivative of the invention also can be delivered to an individual for inhibiting angiogenesis or treating an angiogenesis-dependent disease by administering an encoding nucleic acid for the peptide. Therefore, the encoding nucleic acids for the SNS tripeptides, analogues, mimetics and chemical derivatives of the invention are useful in conjunction with a wide variety of gene therapy methods known in the art for delivering an angiogenesis inhibitory amount of the peptide or variant.
  • nucleic acids for one or more SNS tripeptides, analogues, mimetics, chemical derivatives or a combination thereof can be incorporated into a vector or delivery system known in the art and used for delivery and expression of the encoding sequence to achieve an angiogenesis inhibitory amount.
  • Applicable vector and delivery systems known in the art include, for example, retroviral vectors, adenovirus vectors, adenoassociated virus, ligand conjugated particles and nucleic acids for targeting, isolated DNA and RNA, liposomes, polylysine, and cell therapy, including hepatic cell therapy, employing the transplantation of cells modified to express SNS tripeptides, as well as various other gene delivery methods and modifications known to those skilled in the art, such as those described in Shea et al., Nature Biotechnol. 17:551-559 (1999), which is incorporated herein by reference.
  • the present invention also relates to encoding nucleic acids and vectors useful in the gene therapy methods and can be prepared by methods known in the art. Compositions containing such nucleic acids, vectors and pharmaceutically acceptable medium are also provided.
  • the pharmaceutically acceptable medium should not contain elements that would degrade the desired nucleic acids.
  • the methods of using SNS tripeptides, analogues, mimetics or chemical derivatives can employ any of the various species of SNS tripeptides, analogues, mimetics and chemical derivatives previously set forth. Non-SNS sequences can impart structural or functional characteristics onto the peptides of the invention.
  • Targeting of an SNS tripeptide, analogue, mimetic or chemical derivative to the site of aberrant angiogenesis confers the additional therapeutic advantage of anchoring the peptide at the site of the pathological condition. This result therefore sustains a high effective concentration of the peptide diffusible into the angiogenic area over time and essentially allows for continuous local administration of SNS tripeptide, analogue, mimetic or chemical derivative to the site of angiogenesis.
  • two or more SNS tripeptides, analogues, mimetics or chemical derivatives of the invention can be administered in the methods of the invention to inhibit angiogenesis or to treat an angiogenesis-dependent disease.
  • one or more SNS tripeptides, analogues, mimetics or chemical derivatives can be administered in combination with one or more SNS tripeptides, analogues, mimetics or chemical derivatives to inhibit angiogenesis or treat an angiogenesis-dependent disease. Therefore, various combinations and permutations of SNS tripeptides, SNS analogues, SNS mimetics and SNS chemical derivatives and combinations thereof can be administered in the methods of the invention for the effective inhibition of angiogenesis and treatment of an angiogenesis-dependent disease.
  • SNS tripeptides, analogues, mimetis and chemical derivatives and combinations thereof can also be delivered in alternating administrations so as to combine their angiogenic inhibiting effects over time.
  • an SNS analogue can be administered in a single bolus dose followed by multiple administrations of one or more SNS tripeptides alone or in combination with an SNS tripeptide, analogue, mimetic or chemical derivative.
  • the mode of administration can be any of those types of administrations described previously and will depend on the particular therapeutic need and efficacy of the SNS tripeptide, analogue, mimetic or chemical derivative selected for the purpose.
  • Determining which species of SNS tripeptide, analogue, mimetic or chemical derivative to combine in a cocktail or to combine in a temporally administered regime will depend on the angiogenesis-dependent disease and the specific physical characteristics of the individual affected with the disease. Those skilled in the art will know or can determine a specific cocktail or regime of administration which is effective for a particular application using the teachings and guidance provided herein together with diagnostic and clinical criteria known within the field of art of the particular angiogenesis-dependent disease.
  • the methods of inhibiting angiogenesis or treating angiogenesis-dependent disease by administering SNS tripeptide, analogue, mimetic or chemical derivative additionally can be practiced in conjunction with other therapies.
  • Possible embodiments of the invention contemplate use of such administration in conjunction with other therapies such as conventional chemotherapy directed against solid tumors and for the control of establishment of metastases.
  • the administration of angiogenesis inhibitor is typically conducted during or after chemotherapy at time where the tumor tissue should respond to toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. Additionally, it is preferred to administer such angiogenesis inhibition procedures after surgery where solid tumors have been removed as a prophylaxis against metastases.
  • Angiogenic inhibitors are known in the art and can be prepared by known methods.
  • angiogenic inhibitors include integrin inhibitory compounds such as ⁇ v integrin inhibitory antibodies, cell adhesion proteins or functional fragments thereof which contain a cell adhesion binding sequence.
  • Additional angiogenic inhibitors include, for example, angiostatin, functional fragments of angiostatin, endostatin, fibroblast growth factor (FGF) inhibitors, FGF receptor inhibitors, VEGF inhibitors, VEGF receptor inhibitors, vascular permeability factor (VPF) inhibitors, VPF receptor inhibitors, thrombospondin, platelet factor 4, interferon-alpha, interferon-gamma, interferon-inducible protein 10, interleukin 12, gro-beta, and the 16 kDa N-terminal fragment of prolactin, thalidomide, and other mechanisms for the inhibition of angiogenesis.
  • Angiostatin is the subject matter of U.S. Patent No. 5,639,725, supra.
  • Endostatin is the subject matter of PCT publication WO 97/15666, supra.
  • endostatin is the subject matter of PCT publication WO 97/15666, supra.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions such as the pharmaceutically acceptable mediums described above.
  • the solutions can additionally contain, for example, anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
  • Other formulations include, for example, aqueous and non-aqueous sterile suspensions which can include suspending agents and thickening agents.
  • the formulations can be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and can be stored in a lyophilized condition requiring, for example, the addition of the sterile liquid carrier, immediately prior to use.
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the kind previously described.
  • a pharmaceutically acceptable medium can additionally contain physiologically acceptable compounds that act, for example, to stabilize or increase the absorption of the SNS tripeptide, analogue, mimetic or chemical derivative.
  • physiologically acceptable compounds include, for example, carbohydrates such as glucose, sucrose or dextrans; antioxidants such as ascorbic acid or glutathione; chelating agents such as EDTA, which disrupts microbial membranes; divalent metal ions such as calcium or magnesium; low molecular weight proteins; lipids or liposomes; or other stabilizers or excipients.
  • An SNS tripeptide, analogue, mimetic or chemical derivative can also be formulated with a pharmaceutically acceptable medium such as a biodegradable polymer.
  • angiogenesis- inhibitory tripeptides can be covalently attached by surface grafting, co-polymerization, non-covalently incorporation into a matrix or otherwise encapsulating as biomedical materials. Modulation, and control of new blood vessel formation is an essential part of approaches to tissue engineering materials where a balance of pro- antiangiogenic and anti-angiogenic factors must be maintained.
  • the tripeptides may be used in conjuction with known promoters of angiogenesis, functional biomedical materials such as implant and prosthetic materials, scaffolds for tissue engineering, wound healing materials, ex vivo artificial organ materials, that modulate new blood vessel formation in tissue.
  • the polymeric formulations may also be used for sustained release of the antiangiogenesis-inhibitory peptides for inhibition of new blood vessel formation. This is one example of a drug delivery method involving conjugation of the antiangiogenesis-inhibitory peptide to a carrier material that can be used to locally deliver the antiangiogenic effects of such a formulation in angiogenesis-dependent diseases.
  • Human umbilical vein endothelial cells (HUVEC), Endothelial cell basal medium (serum-free, EBM), EGM (supplemented with growth factors, fetal calf serum), and 0.025% trypsin/0.01% EDTA solution were purchased from Clonetics Inc. (San Diego, CA).
  • Human prostrate (TSU-Pr) tumor cells were obtained from American Type Culture Collection (RockviUe, MD).
  • Matrigel® matrix and human collagen type III were purchased from Becton Dickinson (Bedford, MA).
  • HEMA-3 fixative and staining solutions were purchased from Biochemical Sciences, Inc. (Swedesboro, NJ). Fertilized chicken eggs were purchased from Charles River Laboratories, SPAFAS Avian Products & Services (North Franklin, CT).
  • HUVEC Human umbilical vein endothelial cells
  • EBM endothelial cell basal medium
  • BSA bovine serum albumin
  • l-T-Se 1 :100 diluted Insulin-Transferrin-Selenium-G supplement
  • PBS phosphate buffered saline
  • FGF2 human fibroblast growth factor basic
  • the medium was aspirated and cells were fixed and stained using a modified HEMA-3 stain kit.
  • Digital images of microtiter well sections were collected using a DKC5000 3-CCD color video camera system (Toshiba America, New York, NY) and analyzed with the Image- Pro Plus software (Media Cybernetics, Silver Spring, MD). The area and major axis length of stained cells having a tubular morphology on the Matrigel® matrix surface (Becton Dickinson, Bedford, PA) counted from 5 images/well.
  • acetyl-Ser-Asn-Ser- carboxamide (Structure 1), acetyl-Asn-Tyr-Tyr-Ser-Asn-Ser (SEQ ID NO:2), acetyl- Ser-Asn-Ser-Tyr-Ser-Phe-Trp-Leu (SEQ ID NO:3) and acetyl-Cys-Asn-Tyr-Tyr-Ser-Asn-Ser-Tyr-Ser-Phe-Trp-Leu (SEQ ID NO:4).
  • Table 2 illustrates that acetyl-Ser-Asn-Ser-carboxamide (Structure 1) was a more potent inhibitor of FGF2-stimulated EC tube formation in vitro than the larger peptides. Percent inhibition data is expressed as the quotient of the experimental value minus the negative control value (EBM medium) divided by the difference between the positive control value and the negative control value. TABLE 2 Average % Inhibition of EC Tube Formation by Peptides
  • EXAMPLE 2 Neovascularization on the CAM and Microscopic Analysis of CAM Sections
  • In vivo neovascularization was examined by the method previously described by Auerbach et al. (J. Dev. Biol. 41 :391-394 (1974)).
  • Ten-day old embryos were purchased from Spafas, Inc. (Preston, CT) and were incubated at 37°C with 55% relative humidity.
  • a candling lamp a small hole was punctured in the shell concealing the air sac with a hypodermic needle.
  • a second hole was punctured in the shell on the broadside of the egg directly over an vascular portion of the embryonic membrane, as observed during candling.
  • a false air sac was created beneath the second hole by the application of negative pressure to the first hole, which caused the chorioallantoic membrane (CAM) to separate from the shell.
  • a window approximately 1.0 cm 2 , was cut in the shell over the dropped CAM with the use of a small crafts grinding wheel (Dremel, Division of Emerson Electric Company Racine, Wl) which allowed direct access to the underlying CAM.
  • Filter disks of #1 filter paper (Whatman International, United Kingdom) were soaked in 3 mg/mL cortisone acetate (Sigma, St. Louis, MO) in a solution of 95% ethanol and water and subsequently air dried under sterile conditions.
  • FGF2 (Life Technologies, Gaithersburg, MD) was used to grow vessels on the CAMs of 10-d old chick embryos. Sterile filter disks adsorbed with FGF2 dissolved in PBS at 1 ⁇ g/mL were placed on growing CAMs. At 24 h, test compounds or control vehicle was added directly to CAMs topically. CAM tissue directly beneath FGF2-satu rated filter disk was resected from embryos treated 48 h prior with compound or control. Tissues were washed three times with PBS. Sections were placed in a 35-rmm petri dish (Nalge Nunc, Rochester, NY) and examined under a SV6 stereomicroscope (Karl Zeiss, Thornwood, NY) at 50X magnification.
  • Chick Chorioallantoic Membrane Tumor Assays Ten million tumor cells were placed on the surface of each CAM and were cultured for one week. The resulting tumors were excised and cut into 50 mg fragments. These fragments were placed on additional CAMs and treated topically or systemically by intravenous injection the following day with the test agents. Forty-eight hours later, CAMs were excised from the egg and the number of blood vessels entering the tumors were counted (as vessel branch points). Data is presented as mean blood vessel number per treatment group (+/- standard error of measurement). Each treatment group incorporated at least ten tumors per experiment. Tumors were then excised from the egg and tumor weights were determined for each tumor.
  • TSU-Pr Prostrate Tumor Growth
  • Ten million tumor cells were placed on the surface of each CAM (7-d old embryo) and were cultured for one week. The resulting tumors were excised and cut into 50 mg fragments. These fragments were placed on additional CAMs and treated topically the following day with acetyl-Ser-Asn-Ser-carboxamide (Structure 1 ) or vehicle. Seven days later, CAMs were excised from the egg and the number of blood vessels entering the tumors was counted (as vessel branch points). Data is presented as mean blood vessel number per treatment group (+ standard error of measurement). Each treatment group incorporated at least ten tumors per experiment. Representative tumors were photographed at 10X magnification. Tumors were then excised from the egg and tumor weights were determined for each tumor. Data is presented as mean tumor weight per treatment group (+ standard error of the mean). Statistical analysis was performed using Student's t-test.
  • Acetyl-Ser-Asn-Ser-carboxamide (Structure 1) was shown to inhibit the growth of human prostrate tumors in vivo by direct injection into the tumors (Figure 3). Six tumors out of the ten injected with 45 ⁇ g acetyl- Ser-Asn-Ser-carboxamide (Structure 1) showed significant weight shrinkage after 7 d (111 % ave inhibition at 45(100% ave inhibition at 16 ⁇ g).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des procédés et des compositions inhibant la formation de tubules de cellules endothéliales, premier stade de l'angiogenèse de tumeurs. L'invention porte plus spécialement sur des tripeptides s'étant montré des inhibiteurs de processus médiés par l'angiogenèse. Les séquences d'acides aminés ayant la plus grande préférence sont SNS et SQS.
PCT/US2002/005211 2001-02-16 2002-02-15 Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation WO2002066512A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002566225A JP2005507363A (ja) 2001-02-16 2002-02-15 血管新生阻害トリペプチド、組成物およびそれらの使用方法
EP02714953A EP1360205A1 (fr) 2001-02-16 2002-02-15 Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation
CA002432932A CA2432932A1 (fr) 2001-02-16 2002-02-15 Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26953701P 2001-02-16 2001-02-16
US60/269,537 2001-02-16
US32204701P 2001-09-14 2001-09-14
US60/322,047 2001-09-14

Publications (1)

Publication Number Publication Date
WO2002066512A1 true WO2002066512A1 (fr) 2002-08-29

Family

ID=26953759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005211 WO2002066512A1 (fr) 2001-02-16 2002-02-15 Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP1360205A1 (fr)
JP (1) JP2005507363A (fr)
CN (1) CN1264858C (fr)
CA (1) CA2432932A1 (fr)
WO (1) WO2002066512A1 (fr)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516887A (ja) * 2002-10-30 2006-07-13 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） 血管新生を阻害するｈａｒｐ因子のペプチドフラグメント
WO2009000296A2 (fr) * 2007-06-25 2008-12-31 Oncoreg Ab Composés utilisés dans le traitement de maladies auto-immunes et inflammatoires et le rejet de greffes
US20090305955A1 (en) * 2006-03-23 2009-12-10 Jean-Claude Paul Louis Monboisse Cyclopeptide with Anti-Cancer Activity Derived from Collagen Type IV
WO2010092114A1 (fr) 2009-02-13 2010-08-19 Guerbet Utilisation de tampons pour la complexation de radionucléides
WO2012084981A1 (fr) 2010-12-20 2012-06-28 Guerbet Nanoemulsion de chelate pour irm
WO2013045333A1 (fr) 2011-09-26 2013-04-04 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
US20130237580A1 (en) * 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
WO2014114724A1 (fr) 2013-01-23 2014-07-31 Guerbet Magneto-emulsion vectorisee
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
AU2013207900B2 (en) * 2012-01-12 2017-12-07 Cambridge Enterprise Limited Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US9993514B2 (en) 2013-07-03 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US10865202B2 (en) 2016-09-15 2020-12-15 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101747411B (zh) * 2008-11-28 2012-07-25 北京大学 氨基酰色氨酰色氨酸三肽苄酯及其制备方法和应用
CN101747410B (zh) * 2008-11-28 2013-03-13 北京大学 具镇痛活性的氨基酰酪氨酰色氨酸三肽及制备方法和应用
KR102494803B1 (ko) * 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN110468175A (zh) * 2019-08-22 2019-11-19 赵秋萍 一种复合植物肽粉及其制备方法和用途
US20220370546A1 (en) 2019-11-05 2022-11-24 Kyoto University Peptide, composition, and method for treating, preventing, or ameliorating mood disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051638A1 (fr) * 1998-04-08 1999-10-14 G.D. Searle & Co. LIGANDS DOUBLES DU RECEPTEUR Avb3 ET DU RECEPTEUR ASSOCIE AUX METASTASES
WO1999055861A2 (fr) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051638A1 (fr) * 1998-04-08 1999-10-14 G.D. Searle & Co. LIGANDS DOUBLES DU RECEPTEUR Avb3 ET DU RECEPTEUR ASSOCIE AUX METASTASES
WO1999055861A2 (fr) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLEINERMAN E S ET AL: "UNIQUE HISTOLOGICAL CHANGES IN LUNG METASTASES OF OSTEOSARCOMA PATIENTS FOLLOWING THERAPY WITH LIPOSOMAL MURAMYL TRIPEPTIDE CGP 19835A LIPID", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 34, no. 4, 1992, pages 211 - 220, XP001085411, ISSN: 0340-7004 *
MAESHIMA YOHEI ET AL: "Distinct antitumor properties of a type IV collagen domain derived from basement membrane.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21340 - 21348, XP002204077, ISSN: 0021-9258 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516887A (ja) * 2002-10-30 2006-07-13 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） 血管新生を阻害するｈａｒｐ因子のペプチドフラグメント
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US20090305955A1 (en) * 2006-03-23 2009-12-10 Jean-Claude Paul Louis Monboisse Cyclopeptide with Anti-Cancer Activity Derived from Collagen Type IV
WO2009000296A2 (fr) * 2007-06-25 2008-12-31 Oncoreg Ab Composés utilisés dans le traitement de maladies auto-immunes et inflammatoires et le rejet de greffes
WO2009000296A3 (fr) * 2007-06-25 2009-03-19 Oncoreg Ab Composés utilisés dans le traitement de maladies auto-immunes et inflammatoires et le rejet de greffes
WO2010092114A1 (fr) 2009-02-13 2010-08-19 Guerbet Utilisation de tampons pour la complexation de radionucléides
WO2012084981A1 (fr) 2010-12-20 2012-06-28 Guerbet Nanoemulsion de chelate pour irm
US9770520B2 (en) 2010-12-20 2017-09-26 Guerbet Chelate nanoemulsion for MRI
WO2013045333A1 (fr) 2011-09-26 2013-04-04 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
AU2013207900B2 (en) * 2012-01-12 2017-12-07 Cambridge Enterprise Limited Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US10730862B2 (en) 2012-01-12 2020-08-04 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US20130237580A1 (en) * 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
US9044442B2 (en) * 2012-03-07 2015-06-02 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
WO2014114724A1 (fr) 2013-01-23 2014-07-31 Guerbet Magneto-emulsion vectorisee
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US9993514B2 (en) 2013-07-03 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Compounds
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US11512083B2 (en) 2015-03-18 2022-11-29 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
US11554171B2 (en) 2015-08-19 2023-01-17 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US10865202B2 (en) 2016-09-15 2020-12-15 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
US11584743B2 (en) 2016-09-15 2023-02-21 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
US11952347B2 (en) 2016-10-11 2024-04-09 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11964945B2 (en) 2016-10-11 2024-04-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10844021B2 (en) 2016-10-11 2020-11-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11236051B2 (en) 2016-10-11 2022-02-01 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11104666B2 (en) 2016-12-01 2021-08-31 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11597720B2 (en) 2016-12-01 2023-03-07 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11986531B2 (en) 2016-12-23 2024-05-21 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11857519B2 (en) 2016-12-24 2024-01-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11384063B2 (en) 2017-01-26 2022-07-12 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11834460B2 (en) 2018-01-26 2023-12-05 Yale University Imide-based modulators of proteolysis and associated methods of use
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Also Published As

Publication number Publication date
EP1360205A1 (fr) 2003-11-12
CN1561344A (zh) 2005-01-05
CA2432932A1 (fr) 2002-08-29
JP2005507363A (ja) 2005-03-17
CN1264858C (zh) 2006-07-19

Similar Documents

Publication Publication Date Title
US6815426B2 (en) Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002066512A1 (fr) Tripeptides inhibiteurs de l'angiogenese, compositions, et leurs procedes d'utilisation
US5192746A (en) Cyclic cell adhesion modulation compounds
EP0488258B1 (fr) Dérivés de propenamide, leur polymères, copolymères et leur emploi
US6548477B1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AU764277B2 (en) Peptide antiangiogenic drugs
AU604944B2 (en) Cysteine proteinase inhibitor
EP0443404A1 (fr) Fragments peptidiques et analogues de thrombospondine
NZ297530A (en) Cyclic peptides that inhibit the interaction of vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with integrin very late antigen 4 (VLA-4)
JPH08502493A (ja) アルギニンケト‐アミド酵素阻害剤
US6638912B2 (en) Peptide compositions mimicking TGF-β activity
US7115562B2 (en) Peptides and their use to ameliorate cell death
WO1992013552A1 (fr) Peptides inhibant l'aggregation et contenant un amide ou un ester aromatique
EP0514721B1 (fr) Peptides ayant une activité de type thrombospondine et leur utilisation thérapeutique
JPH08511794A (ja) ▲ｖｉｉ▼因子由来ペプチド
EP0397635A1 (fr) Peptide avec une activité antimétastatique
US5721210A (en) Cyclic cell adhesion modulation compounds
US6703364B2 (en) Thrombin generation inhibitors
US20050124548A1 (en) Peptide antiangiogenic drugs
Witkowska et al. New analogues of laminin active fragment YIGSR: synthesis and biological activity in vitro and in vivo
JPH06116287A (ja) プロペンアミド誘導体、その重合物およびその用途
JP2745343B2 (ja) プロペンアミド誘導体とカチオン性単量体との共重合物およびその用途
JP2649871B2 (ja) 疎水性単量体、該疎水性単量体とプロペンアミド誘導体単量体の共重合物およびその用途
JP2620728B2 (ja) ペプチド含有ポリエチレングリコール誘導体とその用途
JP2745342B2 (ja) プロペンアミド誘導体、その重合物およびその用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2432932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002714953

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002566225

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028051122

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002714953

Country of ref document: EP